Quercetin might help with hair loss by inhibiting HSP-70, which increases androgen receptors. Concerns include its staining properties and unclear topical absorption.
The conversation is about finding an affordable and effective low level laser therapy device for hair loss, with a preference for a cap but open to a comb.
The conversation discusses the cost-effectiveness of using premade RU58841 versus making it from powder for hair loss treatment. It also questions whether higher concentrations are more effective for women.
The conversation is about purchasing RU58841 for hair loss treatment from Xian Lyphar BioTech. Users confirm the company is legitimate and the price is reasonable.
The user had lab work done to check for thyroid issues and other factors related to hair loss. They are seeking advice on which lab results are important for understanding hair loss and what the optimal levels should be.
Low-level laser therapy (LLLT) is discussed as a supplementary treatment for hair loss, with users recommending brands like LaserCap, Ideatherapy, Capillus Pro, and iRestore Pro. Users suggest combining LLLT with treatments like minoxidil and finasteride for better results.
The conversation discusses the ineffectiveness of tablet forms of dutasteride for hair loss due to poor absorption compared to soft gel capsules. It suggests switching to FDA-approved soft gel capsules for better results, as tablets may not adequately suppress DHT levels.
The conversation is about seeking advice on the potential benefits of two different hair sprays for hair loss, with a list of ingredients provided for each. Specific treatments were not discussed.
A user is considering a $5,295 one-year hair loss program from HairClub/Bosley, which includes treatments like finasteride, minoxidil, and a DNA test to personalize treatment. Opinions are mixed, with some suggesting cheaper alternatives like standard medications and questioning the value of the program.
The conversation confirms that to make a 5% RU58841 solution, 1.5 grams should be added to 30 mL of KB Solution. The discussion involves calculating the correct dosage for hair loss treatment.
The conversation is about comparing keratin hair fibers to Gossypium Herbaceum hair fibers for diffuse hair loss. The user prefers keratin fibers for their durability and is seeking a bulk purchase option.
The post discusses the high cost of a topical hair loss treatment from Happy Head, which contains finasteride, minoxidil, retinoic acid, and hydrocortisone. The user is seeking cheaper alternatives, specifically asking if there are compounding pharmacies that can recreate the same or similar formulation.
Procapil is marketed as a natural hair loss treatment but lacks strong evidence and is industry-biased. Minoxidil and Finasteride are the only FDA-approved treatments for androgenetic alopecia.
PP405 is a new hair loss treatment facing mixed reactions due to initial hype and insufficient data. Some are hopeful, but many doubt its effectiveness compared to minoxidil and finasteride.
Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.
Minoxidil, dutasteride, and copper peptides are used in a tattooing method for hair regrowth, with some users noting better results compared to oral treatments. Copper peptides are considered to have minimal impact, but the method may reduce side effects.
RU58841 for hair loss, discussing sources, application methods, and carriers like PG + ethanol or liquid minoxidil. Users share experiences with premixed solutions and powder forms, noting price differences and storage importance.
New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.
The conversation is about sourcing RU58841 for hair loss treatment, with a focus on finding reputable sellers. The user plans to use 10mg/ml daily, split into two doses, prioritizing quality over price.
The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.
PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.
The user is using a combination of oral Dutasteride and Minoxidil, and a topical formula with Finasteride, Minoxidil, and Hydrocortisone, along with rosemary oil, coconut oil, ginseng, and a derma roller. They are also using LLLT therapy and are questioning the timing of the laser cap session in relation to the topical application.
The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.
Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
Treatments for hair loss, such as minoxidil, finasteride, and RU58841; humorous posts about hair loss; and the choice to stop using treatments in exchange for a different look.
Low-level laser therapy (LLLT) stimulates hair growth but current devices are expensive. A proposed non-profit project aims to create affordable, 3D-printed LLLT devices and collect data on their effectiveness.
Breezula's phase 3 results are expected soon, but its release is likely delayed until 2027 or 2028. The discussion highlights the need for more hair growth stimulants like AMP-303 and PP-405, as current treatments like Dutasteride effectively stop hair loss but don't regrow hair.
A user shared their initial experiences with The Ordinary hair density serum, which contains Redensyl (taxifolin). They observed increased hair volume but also developed pimples, likely due to the serum stimulating sebaceous glands.
The conversation is about the lack of discussion on Low-level laser light therapy (LLLT) laser caps for hair loss. One user questions their effectiveness, and another asserts they don't work.